The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
01-Sep-17
$NA
Target:
B-G Mechanical Contractors, Inc., B-G Mechanical Services, Inc., Elmsford Sheet Metal Works, Inc., Fred Williams, Inc., H.T. Lyons, Inc. and TryState Mechanical, Inc.
Acquiror:
ENGIE North America
Advised Talen Energy, one of the largest independent energy and power producers in the United States, on the sale of six subsidiaries, within its Mechanical Services business, to Engie North America
31-Jul-17
$NA
Target:
General Control Systems, Inc.
Acquiror:
Management
Advised Talen Energy, one of the largest independent energy and power producers in the United States, on the sale of General Control Systems, within its Mechanical Services business, to management
13-Jul-17
$1.5 billion
Target:
L.L.Bean (Credit Card Assets)
Acquiror:
Citibank, N.A.
Advised L.L.Bean Inc. on a strategic alliance relating to its credit card business with Citibank, N.A.
12-Jul-17
$227 million
Target:
Wells Fargo Share Registration & Service business
Acquiror:
Equiniti Group plc
Advised Equiniti Group plc, a UK based specialist technology outsourcer providing non-discretionary payment and administration services, on the acquisition of Wells Fargo's Shareowner Services business, and acted as joint sponsor to Equiniti's associated £122 million rights issue
30-Jun-17
$NA
Target:
Millennium Builders, Inc.
Acquiror:
Management
Advised Talen Energy, one of the largest independent energy and power producers in the United States, on the sale of Millennium Builders, within its Mechanical Services business, to management
26-May-17
$415 million
Target:
Chromalox
Acquiror:
Spirax Sarco
Advised Chromalox, a leading provider of electrical products, systems and solutions for industrial process heating and temperature management, on its sale to Spirax Sarco, a global engineering group
11-May-17
$245 million
Target:
Equity stake in Bupa Arabia
Acquiror:
Bupa Ltd.
Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia
05-May-17
$NA
Target:
Burns Mechanical, Inc. and McClure Company
Acquiror:
Management and Outside Investors
Advised Talen Energy, one of the largest independent energy and power producers in the United States, on the sale of two of its subsidiaries, within its Mechanical Services business, to management and outside investors
03-Apr-17
$205 million
Target:
Inenco Group Pty Ltd
Acquiror:
Genuine Parts Company
Advised Inenco Group Pty Ltd, one of Australasia’s leading industrial distributors, on the partial sale to Genuine Parts Company, a global distributor of automotive and industrial products
03-Jan-17
$536 million
Target:
LCH.Clearnet SA
Acquiror:
Euronext N.V.
Advised LCH.Clearnet Group Limited, a leading multi-asset class European clearing house, on a sale of LCH.Clearnet SA, its French-regulated operating subsidiary, to Euronext N.V. that was ultimately terminated
12-Dec-16
$NA
Target:
Gradifi, Inc.
Acquiror:
First Republic Bank
Advised First Republic Bank, a provider of private banking, private business banking and private wealth management services, on the acquisition of Gradifi, a Boston-based technology and service platform used by employers to make direct contributions to employees’ student loans
03-Nov-16
$3.3 billion
Target:
Metaldyne Performance Group, Inc.
Acquiror:
American Axle & Manufacturing Holdings, Inc.
Advised American Axle & Manufacturing Holdings, Inc., a leading manufacturer of driveline and drivetrain systems and related components and metal-formed products, on the acquisition of Metaldyne Performance Group, Inc., a provider of highly-engineered lightweight components for use in powertrain and suspension applications for the global light, commercial and industrial vehicle markets
13-Oct-16
$NA
Target:
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
18-Aug-16
$3.2 billion
Target:
Valves & Controls Business of Pentair
Acquiror:
Emerson
Advised Emerson, a diversified global technology and industrial company, on the acquisition of the Valves & Controls business of Pentair
08-Aug-16
$87 million
Target:
Aquasana, Inc.
Acquiror:
A. O. Smith Corporation
Advised A. O. Smith Corporation, a leading manufacturer of residential and commercial water heaters and boilers, on the acquisition of Aquasana, a premium water treatment company, from L Catterton
28-Jul-16
$80 million
Target:
BioD, LLC
Acquiror:
Derma Sciences, Inc.
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
28-Jun-16
$NA
Target:
US rights to an authorized generic version of Adderall XR
Acquiror:
Prasco Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
20-Jun-16
$NA
Target:
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
15-Jun-16
$414 million
Target:
Aegerion Pharmaceuticals
Acquiror:
QLT Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories